15.06.2011 – 17:58

SYGNIS AG

EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG secures further financial resources with shareholder loan

--------------------------------------------------------------------------------
  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
15.06.2011

Ad-hoc


SYGNIS Pharma AG secures further financial resources with shareholder loan

Heidelberg,  15  June  2011  -  SYGNIS  Pharma   AG   (Frankfurt:   LIOK;   ISIN
DE000A1E9B74; Prime Standard) today executed a subordinated loan  agreement  for
a total amount of EUR 6 million with its main shareholder dievini  Hopp  BioTech
holding GmbH & Co. KG, Walldorf, Germany (dievini),  with  an  interest-rate  at
customary market conditions. As a result this loan, which is payable on  demand,
secures the financing of SYGNIS´ existing operations, according to  the  present
plans, at least until the end of 2012.

The loan is unsecured, bears no expiry date and may be terminated not before  30
September 2012. In this case the loan  is  to  be  repaid  within  a  one  month
period. The loan agreement will be  dissolved  through  dievini´s  corresponding
participation in  a  future  capital  increase  with  shareholders  subscription
rights. In addition, instead of requesting a repayment of the loan,  dievini  is
entitled to a repayment by way of a contribution in kind as part  of  a  capital
increase with shareholders subscription rights. Alternatively repayment  can  be
made in return for shares by way of a convertible bond programme, which  is  yet
to be agreed upon. Prerequisite for these repayment options are  the  resolution
and execution of a capital increase with shareholders subscription rights  or  a
convertible bond programme as well as the creation of  the  conditional  capital
necessary for the second option  through  decision  of  SYGNIS´  Annual  General
Meeting and registration in the commercial register.


For further information please contact:


|Peter Willinger                         |
|CFO                                     |
|Tel: +49 (0) 6221-454 836               |
|Email:  peter.willinger@sygnis.de        |
|                                        |

###

Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.
###


Further inquiry note:
Michael Wolf
Telefon: +49 (0) 6221 454 - 745
E-Mail:  Michael.Wolf@sygnis.de

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
mail:         contact@sygnis.de
WWW:         http://www.sygnis.de
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language: English